Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study

Leigh Perreault, Marinella Temprosa, Kieren J Mather, Ed Horton, Abbas Kitabchi, Mary Larkin, Maria G Montez, Debra Thayer, Trevor J Orchard, Richard F Hamman, Ronald B Goldberg, Diabetes Prevention Program Research Group, Leigh Perreault, Marinella Temprosa, Kieren J Mather, Ed Horton, Abbas Kitabchi, Mary Larkin, Maria G Montez, Debra Thayer, Trevor J Orchard, Richard F Hamman, Ronald B Goldberg, Diabetes Prevention Program Research Group

Abstract

Objective: Restoration of normal glucose regulation (NGR) in people with prediabetes significantly decreases the risk of future diabetes. We sought to examine whether regression to NGR is also associated with a long-term decrease in cardiovascular disease (CVD) risk.

Research design and methods: The Framingham (2008) score (as an estimate of the global 10-year CVD risk) and individual CVD risk factors were calculated annually for the Diabetes Prevention Program Outcomes Study years 1-10 among those patients who returned to NGR at least once during the Diabetes Prevention Program (DPP) compared with those who remained with prediabetes or those in whom diabetes developed during DPP (N = 2,775).

Results: The Framingham scores by glycemic exposure did not differ among the treatment groups; therefore, pooled estimates were stratified by glycemic status and were adjusted for differences in risk factors at DPP baseline and in the treatment arm. During 10 years of follow-up, the mean Framingham 10-year CVD risk scores were highest in the prediabetes group (16.2%), intermediate in the NGR group (15.5%), and 14.4% in people with diabetes (all pairwise comparisons P < 0.05), but scores decreased over time for those people with prediabetes (18.6% in year 1 vs. 15.9% in year 10, P < 0.01). The lower score in the diabetes group versus other groups, a declining score in the prediabetes group, and favorable changes in each individual risk factor in all groups were explained, in part, by higher or increasing medication use for lipids and blood pressure.

Conclusions: Prediabetes represents a high-risk state for CVD. Restoration of NGR and/or medical treatment of CVD risk factors can significantly reduce the estimated CVD risk in people with prediabetes.

© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Figures

Figure 1
Figure 1
Participant flow through DPP, DPPOS, and this study.
Figure 2
Figure 2
Trajectories of 10-year CVD risk during the DPPOS in people with diabetes (solid), prediabetes (medium dash), and NGR (short dash) represented by means (lines) and 95% CIs (gray dotted line) with adjustment for differences in treatment group, age at randomization, sex, race/ethnicity, and baseline CVD risk factors (TC concentration, SBP or use of antihypertensive medication, smoking status, diagnosis of diabetes, and/or HDL-C concentration).
Figure 3
Figure 3
Trends represented by means (lines) and 95% CIs (gray dotted line) for use of lipid-lowering medications (A), TC concentration (B), LDLconcentration (C), use of blood pressure–lowering medications (D), SBP (E), and DBP (F) over 10 years of the DPPOS in people with diabetes (solid), prediabetes (medium dash), and NGR (short dash) with adjustment for treatment group.

References

    1. Buchanan TA, Xiang AH, Peters RK, et al. . Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796–2803
    1. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–2077
    1. Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991;34:891–898
    1. Gerstein HC, Yusuf S, Bosch J, et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    1. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–161
    1. Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350
    1. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research Group . Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243–2251
    1. Yakubovich N, Gerstein HC. Is regression to normoglycaemia clinically important? Lancet 2012;379:2216–2218
    1. Diabetes Prevention Program Research Group . The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007;24:137–144
    1. Cheng YJ, Gregg EW, Geiss LS, et al. . Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care 2009;32:2027–2032
    1. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010;55:1310–1317
    1. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group . Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008;31:464–469
    1. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853
    1. Duckworth W, Abraira C, Moritz T, et al. VADT Investigators . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–139
    1. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559
    1. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572
    1. Xiang AH, Hodis HN, Kawakubo M, et al. . Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis 2008;199:207–214
    1. DeFronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW Study . Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104–1115
    1. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–494
    1. Murphy EF, Cotter PD, Healy S, et al. . Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010;59:1635–1642
    1. Pakoskey AM, Lesher EC, Scott DB. Hexokinase of Escherichia coli. Assay of enzyme activity and adaptation to growth in various media. J Gen Microbiol 1965;38:73–80
    1. Tataranni PA, Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 2005;54:917–927
    1. Wilson A, Morrell J. Prevention of heart disease in general practice: the use of a risk score. Health Trends 1991;23:69–73
    1. D’Agostino RB, Sr, Vasan RS, Pencina MJ, et al. . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–753
    1. D’Agostino RB, Sr, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group . Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180–187
    1. Knowler WC, Fowler SE, Hamman RF, et al. Diabetes Prevention Program Research Group . 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677–1686
    1. The Diabetes Prevention Program . The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623–634
    1. Diggle P, Heagerty P, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. New York, Oxford University Press, 1994
    1. Edwards LJ, Muller KE, Wolfinger RD, Qaqish BF, Schabenberger O. An R2 statistic for fixed effects in the linear mixed model. Stat Med 2008;27:6137–6157
    1. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF, Diabetes Prevention Program Research Group . Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 2009;32:1583–1588
    1. Goldberg RB, Temprosa M, Haffner S, et al. Diabetes Prevention Program Research Group . Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009;32:726–732
    1. Orchard TJ, Temprosa M, Barrett-Connor E, et al. Diabetes Prevention Program Outcomes Study Research Group . Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med 2013;30:46–55
    1. Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014;129:e28–e292
    1. Stone NJ, Robinson J, Lichtenstein AH, et al. . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 12 November 2013. [Epub ahead of print]
    1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234
    1. Turner RC, Millns H, Neil HA, et al. . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823–828
    1. Wing RR, Bolin P, Brancati FL, et al. Look AHEAD Research Group . Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145–154
    1. The Diabetes Prevention Program Research Group . The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000;23:1619–1629
    1. Orchard TJ, Temprosa M, Goldberg R, et al. Diabetes Prevention Program Research Group . The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611–619
    1. Trials of Hypertension Prevention, Phase I . The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 1992;267:1213–1220
    1. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002;136:493–503
    1. Chan DC, Watts GF, Ng TW, Yamashita S, Barrett PH. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Eur J Clin Invest 2008;38:743–751
    1. Lee S, Burns SF, White D, Kuk JL, Arslanian S. Effects of acute exercise on postprandial triglyceride response after a high-fat meal in overweight black and white adolescents. Int J Obes (Lond) 2013;37:966–971
    1. Leenen R, van der Kooy K, Meyboom S, Seidell JC, Deurenberg P, Weststrate JA. Relative effects of weight loss and dietary fat modification on serum lipid levels in the dietary treatment of obesity. J Lipid Res 1993;34:2183–2191
    1. Williams PT, Wood PD, Krauss RM, et al. . Does weight loss cause the exercise-induced increase in plasma high density lipoproteins? Atherosclerosis 1983;47:173–185
    1. Mavros Y, Kay S, Anderberg KA, et al. . Changes in insulin resistance and HbA1c are related to exercise-mediated changes in body composition in older adults with type 2 diabetes: interim outcomes from the GREAT2DO trial. Diabetes Care 2013;36:2372–2379
    1. Grundy SM, Howard B, Smith S, Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002;105:2231–2239
    1. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013;36:2271–2279

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner